Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?

Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often happens, the excitement on Wall Street overstated the opportunity. At this point, the stock has lost over two-thirds of its value since mid-2024.Could high-yield Pfizer (NYSE: PFE) be a better investment opportunity?Finding new drug candidates is hard and expensive. Developing and testing a promising candidate is hard and expensive. Navigating the regulatory process to bring a promising candidate to market is hard and expensive. Throughout the entire process, companies are in a race with other pharmaceutical companies to be the first to market with novel treatments.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool